BridgeMD
New treatment option for Substance Use
Official title Neurobehavioral Signatures of Sign- and Goal-Tracking in Emerging Adults: Translation of a Preclinical Model
ClinicalTrials.gov ID: NCT07094061
What this study is testing
- What it's testing
- This study seeks to understand individual differences in personality, brain function, and behavior. Study hypothesis: \- A stronger sign-tracking bias will be associated with a bottom-up processing style characterized by less adaptive attentional- and impulse-control as well as hyperactive reward processing, whereas a stronger goal-tracking bias will be associated with a top-down processing style characterized by strong attentional- and impulse-control as well as normative reward processing.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 22. Healthy volunteers may be eligible.
You may be able to join if
- 18-22 years old at baseline
- Right-handed
- Medically/physically able to give informed consent
- English-speaking
- Substance use is free to vary, but for participants with a history of substance use, ≥ 1 use of cannabis (including less than a full dose)
You likely can't join if
- Acute or chronic medical or neurological illness (e.g., diabetes, epilepsy, migraine)
- History of psychosis in self or first-degree relative
- Current treatment for substance use disorder
- Current or past 6-month treatment with centrally acting medications (not including attention deficit hyperactivity disorder (ADHD) medication)
- Intelligence quotient (IQ) \< 70
- Lifetime history of head trauma with loss of consciousness \> 5 minutes
See the full eligibility criteria
- 18-22 years old at baseline
- Right-handed
- Medically/physically able to give informed consent
- English-speaking
- Substance use is free to vary, but for participants with a history of substance use, ≥ 1 use of cannabis (including less than a full dose)
- Acute or chronic medical or neurological illness (e.g., diabetes, epilepsy, migraine)
- History of psychosis in self or first-degree relative
- Current treatment for substance use disorder
- Current or past 6-month treatment with centrally acting medications (not including attention deficit hyperactivity disorder (ADHD) medication)
- Intelligence quotient (IQ) \< 70
- Lifetime history of head trauma with loss of consciousness \> 5 minutes
- Reliance on glasses to be able to read small text at a distance of approximately 30 inches
- Colorblindness
- MRI contraindication (e.g., pregnancy, metal implants, claustrophobia) per protocol
The study team makes the final eligibility decision.
Where it's taking place
- Ann Arbor, Michigan, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 22 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ann Arbor, Michigan, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.